Cargando…

Managing Lung Cancer with Comorbid Interstitial Pneumonia

Systemic therapy for advanced non-small cell lung cancer (NSCLC) has dramatically changed in the latest 15 years. Molecular-targeted therapy has brought about an era of precision medicine, and immune checkpoint inhibitors have brought hope for a cure for advanced NSCLC. In the wake of this remarkabl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ichihara, Eiki, Miyahara, Nobuaki, Maeda, Yoshinobu, Kiura, Katsuyuki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Japanese Society of Internal Medicine 2019
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7008037/ https://www.ncbi.nlm.nih.gov/pubmed/31534086 http://dx.doi.org/10.2169/internalmedicine.3481-19

Ejemplares similares

Successful Re-administration of Osimertinib in Osimertinib-induced Interstitial Lung Disease with an Organizing Pneumonia Pattern: A Case Report and Literature Review
por: Itano, Junko, et al.
Publicado: (2019)

Interstitial Pneumonia Secondary to Hermansky-Pudlak Syndrome Type 4 Treated with Different Antifibrotic Agents
por: Itano, Junko, et al.
Publicado: (2020)

Intravenous immunoglobulin for acute exacerbation of fibrotic idiopathic interstitial pneumonias
por: Higo, Hisao, et al.
Publicado: (2022)

Clinical significance of repeat rebiopsy in detecting the EGFR T790M secondary mutation in patients with non-small cell lung cancer
por: Ichihara, Eiki, et al.
Publicado: (2018)

Marginal Zone Lymphoma and Lung Adenocarcinoma with an EGFR Exon 19 E746-S752del Mutation in a Patient with IgG4-related Disease
por: Okawa, Sachi, et al.
Publicado: (2021)

Utility of immune checkpoint inhibitors in non‐small‐cell lung cancer patients with poor performance status
por: Kano, Hirohisa, et al.
Publicado: (2020)

Pulmonary Aspergilloma and Allergic Bronchopulmonary Aspergillosis Following the 2018 Heavy Rain Event in Western Japan
por: Ando, Eri, et al.
Publicado: (2021)

Treatment-Related Death in Patients with Small-Cell Lung Cancer in Phase III Trials over the Last Two Decades
por: Ochi, Nobuaki, et al.
Publicado: (2012)

Congestive Heart Failure During Osimertinib Treatment for Epidermal Growth Factor Receptor (EGFR)-mutant Non-small Cell Lung Cancer (NSCLC)
por: Watanabe, Hiromi, et al.
Publicado: (2017)

Successful and Prompt Treatment with Tepotinib for Lung Adenocarcinoma Harboring MET Exon 14 Skipping Mutation Combined with Lung Abscess Formation: A Case Report
por: Makimoto, Go, et al.
Publicado: (2022)

The Effect of Pleural Effusion on Prognosis in Patients with Non-Small Cell Lung Cancer Undergoing Immunochemotherapy: A Retrospective Observational Study
por: Nishimura, Tomoka, et al.
Publicado: (2022)

Role of Survival Post-Progression in Phase III Trials of Systemic Chemotherapy in Advanced Non-Small-Cell Lung Cancer: A Systematic Review
por: Hotta, Katsuyuki, et al.
Publicado: (2011)

Triple therapy with osimertinib, bevacizumab and cetuximab in EGFR-mutant lung cancer with HIF-1α/TGF-α expression
por: Nishii, Kazuya, et al.
Publicado: (2021)

Massive hemoptysis in a post-operative patient with recurrent lung cancer successfully treated by the combination therapy of Endobronchial Watanabe Spigot and bronchial artery embolization
por: Taoka, Masataka, et al.
Publicado: (2022)

Identification of targetable kinases in idiopathic pulmonary fibrosis
por: Higo, Hisao, et al.
Publicado: (2022)

A case of axillary lymphadenitis caused by Mycobacterium intracellulare in an immunocompetent patient
por: Itano, Junko, et al.
Publicado: (2019)

MET or NRAS amplification is an acquired resistance mechanism to the third-generation EGFR inhibitor naquotinib
por: Ninomiya, Kiichiro, et al.
Publicado: (2018)

Current Treatment Strategies for Non-Small-Cell Lung Cancer with Comorbid Interstitial Pneumonia
por: Ikeda, Satoshi, et al.
Publicado: (2021)

Comorbidities in interstitial lung diseases
por: Margaritopoulos, George A., et al.
Publicado: (2017)

Long-term spontaneous remission with active surveillance in IgG4-related pleuritis: A case report and literature review
por: Makimoto, Go, et al.
Publicado: (2019)

Beneficial Effect of Osimertinib Readministration in Non-small-cell Lung Cancer Harboring an Epidermal Growth Factor Receptor (EGFR) Mutation with a History of Acquired Resistance to Osimertinib
por: Makimoto, Go, et al.
Publicado: (2019)

Efficacy of gilteritinib in comparison with alectinib for the treatment of ALK‐rearranged non‐small cell lung cancer
por: Ando, Chihiro, et al.
Publicado: (2023)

Combined effect of cabozantinib and gefitinib in crizotinib‐resistant lung tumors harboring ROS1 fusions
por: Kato, Yuka, et al.
Publicado: (2018)

CDK4/6 signaling attenuates the effect of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer
por: Hara, Naofumi, et al.
Publicado: (2023)

Pneumocystis Pneumonia Concomitant with Ectopic ACTH Syndrome Caused by a Large Cell Neuroendocrine Carcinoma of the Thymus
por: Oda, Naohiro, et al.
Publicado: (2017)

A retinoid X receptor partial agonist attenuates pulmonary emphysema and airway inflammation
por: Morichika, Daisuke, et al.
Publicado: (2019)

The Role of STAT3 in Non-Small Cell Lung Cancer
por: Harada, Daijiro, et al.
Publicado: (2014)

Pharmacotherapy for lung cancer with comorbid interstitial pneumonia: limited evidence requires appropriate evaluation
por: Ishida, Yuriko, et al.
Publicado: (2022)

VEGFR2 blockade augments the effects of tyrosine kinase inhibitors by inhibiting angiogenesis and oncogenic signaling in oncogene‐driven non‐small‐cell lung cancers
por: Watanabe, Hiromi, et al.
Publicado: (2021)

Dasatinib-induced massive left chylothorax in a patient with chronic myeloid leukemia
por: Makimoto, Go, et al.
Publicado: (2022)

Mechanisms of Acquired Resistance to ALK Inhibitors and the Rationale for Treating ALK-positive Lung Cancer
por: Isozaki, Hideko, et al.
Publicado: (2015)

Safety of anti‐SARS‐CoV‐2 messenger RNA vaccine in lung cancer patients undergoing anticancer chemotherapy: A multicenter, prospective, observational, patient‐reported outcome study
por: Harada, Daijiro, et al.
Publicado: (2022)

Demand for weekend outpatient chemotherapy among patients with cancer in Japan
por: Katayama, Hideki, et al.
Publicado: (2020)

Reply to: Pharmacotherapy for lung cancer with comorbid interstitial pneumonia: limited evidence requires appropriate evaluation
por: Funke-Chambour, Manuela, et al.
Publicado: (2022)

Short‐term safety of an anti‐severe acute respiratory syndrome coronavirus 2 messenger RNA vaccine for patients with advanced lung cancer treated with anticancer drugs: A multicenter, prospective, observational study
por: Tamura, Tomoki, et al.
Publicado: (2021)

A Long-term Response to Nivolumab in a Case of PD-L1-negative Lung Adenocarcinoma with an EGFR Mutation and Surrounding PD-L1-positive Tumor-associated Macrophages
por: Watanabe, Hiromi, et al.
Publicado: (2019)

Triplet therapy with afatinib, cetuximab, and bevacizumab induces deep remission in lung cancer cells harboring EGFR T790M in vivo
por: Kudo, Kenichiro, et al.
Publicado: (2017)

Twenty-Seven Years of Phase III Trials for Patients with Extensive Disease Small-Cell Lung Cancer: Disappointing Results
por: Oze, Isao, et al.
Publicado: (2009)

Korean Guidelines for Diagnosis and Management of Interstitial Lung Diseases: Part 3. Idiopathic Nonspecific Interstitial Pneumonia
por: Lee, Jongmin, et al.
Publicado: (2019)

Comorbidities in unclassifiable interstitial lung disease
por: Prior, Thomas Skovhus, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_8iguis6quth4s73pj7lq9hs6t8